Publicaciones en las que colabora con J.L. Sánchez Menoyo (13)

2023

  1. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  2. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180

    Computer methods and programs in biomedicine

2021

  1. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, Vol. 208

2020

  1. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

2018

  1. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

    Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652

2017

  1. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  2. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349

2015

  1. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

    JAMA Neurology, Vol. 72, Núm. 4, pp. 405-413

  2. Defining reliable disability outcomes in multiple sclerosis

    Brain, Vol. 138, Núm. 11, pp. 3287-3298

  3. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

    Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435